0.524

4.76% 0.0238

Mink Therapeutics Inc (INKT)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$0.5002

Aprire:

$0.5252

Volume 24 ore:

101.45K

Relative Volume:

2.39

Capitalizzazione di mercato:

$20.72M

Reddito:

Utile/perdita netta:

$-24.77M

Rapporto P/E:

-0.6805

EPS:

-0.77

Flusso di cassa netto:

$-17.36M

1 W Prestazione:

-14.94%

1M Prestazione:

-25.66%

6M Prestazione:

-39.78%

1 anno Prestazione:

-47.60%

Intervallo 1D:

$0.48

$0.5252

Intervallo di 1 settimana:

$0.4632

$0.63

Portata 52W:

$0.4632

$1.90

Mink Therapeutics Inc Stock (INKT) Company Profile

Nome

Mink Therapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

212-994-8250

Indirizzo

149 FIFTH AVENUE, NEW YORK

Dipendente

Cinguettio

Prossima data di guadagno

2024-08-13

Ultimi documenti SEC

INKT's Discussions on Twitter

Confronta INKT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INKT Mink Therapeutics Inc	0.524	20.72M	0	-24.77M	-17.36M	-0.73
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Mink Therapeutics Inc Borsa (INKT) Ultime notizie

Dec 18, 2024

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting - GlobeNewswire

Dec 18, 2024

Dec 17, 2024

Mink Therapeutics stock hits 52-week low at $0.56 amid market challenges - Investing.com Canada

Dec 17, 2024

Dec 16, 2024

Mink Ventures Commences Diamond Drill Program at Warren Nickel Copper Cobalt Project, Timmins, Ontario - Yahoo Finance

Dec 16, 2024

Dec 05, 2024

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs - Business Wire

Dec 05, 2024

Dec 04, 2024

FairJourney Biologics Appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering - BioSpace

Dec 04, 2024

Nov 28, 2024

Arovella heads toward clinic with CAR-19-iNKT cells - BioWorld Online

Nov 28, 2024

Nov 27, 2024

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire

Nov 27, 2024

Nov 22, 2024

Geenex Developed Mink Solar Project Approved by Ohio Power Siting Board - Yahoo Finance

Nov 22, 2024

Analyzing MiNK Therapeutics (NASDAQ:INKT) & Replimune Group (NASDAQ:REPL) - Defense World

Nov 22, 2024

Comparing Fractyl Health (GUTS) and Its Peers - Defense World

Nov 22, 2024

Nov 19, 2024

MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird - Defense World

Nov 19, 2024

Nov 17, 2024

Midwest Energy Emissions Becomes Birchtech Corp. and Announces Equity Incentive Plan AmendmentsOn October 29, 2024, Birchtech Corp. (formerly Midwest Energy Emissions Corp.) filed a Form 8-K with the SEC, detailing recent corporate changes and u - Defense World

Nov 17, 2024

Bright Mountain Media, Inc. Enters into Executive Employment Agreement with CEO Matthew DrinkwaterOn November 8, 2024, Bright Mountain Media, Inc. (OTCMKTS:BMTM) announced in an 8-K filing that they had entered into an Executive Employment Agr - Defense World

Nov 17, 2024

Nov 15, 2024

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

MiNK Therapeutics stock target cut, rating held amid pipeline updates By Investing.com - Investing.com UK

Nov 15, 2024